Public Employees Retirement System of Ohio Has $101,000 Position in Enanta Pharmaceuticals, Inc. $ENTA

Public Employees Retirement System of Ohio reduced its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 39.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,312 shares of the biotechnology company’s stock after selling 8,514 shares during the period. Public Employees Retirement System of Ohio owned about 0.06% of Enanta Pharmaceuticals worth $101,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its position in Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,779 shares during the period. US Bancorp DE acquired a new stake in Enanta Pharmaceuticals during the 1st quarter worth approximately $36,000. GAMMA Investing LLC acquired a new stake in Enanta Pharmaceuticals during the 1st quarter worth approximately $40,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $88,000. Finally, Squarepoint Ops LLC acquired a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $66,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Saturday, September 27th. JMP Securities lifted their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th. Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $14.00 to $20.00 in a research report on Wednesday, October 1st. HC Wainwright initiated coverage on shares of Enanta Pharmaceuticals in a research report on Monday, July 28th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Westpark Capital boosted their price target on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Enanta Pharmaceuticals Stock Down 2.4%

NASDAQ:ENTA opened at $11.08 on Wednesday. The company has a fifty day moving average of $8.49 and a 200-day moving average of $7.06. The firm has a market capitalization of $236.89 million, a P/E ratio of -2.56 and a beta of 0.89. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.40. The company had revenue of $18.31 million during the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. On average, analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.